Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tonia Vincent, Jelena Bezbradica and Alex Clarke have been awarded funding grants by the Medical Research Council (MRC) for different projects.

Tonia Vincent, Jelena Bezbradica, Alex Clarke
Tonia Vincent, Jelena Bezbradica Mirkovic and Alex Clarke

Tonia Vincent will carry out research that will aim to understand how microbes in the gut can protect joints from osteoarthritis. Although osteoarthritis will affect half of us during our lifetime, there are currently no effective drugs to treat the condition or completely alleviate any of the symptoms, so it is hoped that this research may point to new ways of preventing its development or progression.

On receiving the funding, Tonia said "We are very excited to acquire this funding for a project that started in my lab 14 years ago! The project will attempt to unravel how gut derived systemic metabolites alter osteoarthritis; an area that has immediate translational potential."

Jelena Bezbradica Mirkovic will study the NLRP3 – an intracellular sensor of infection and cellular stress important for antimicrobial defence. She said "Excessive NLRP3 activity either due to genetic mutations, or persistent activation, cause inflammation and resulting pathologies.  Therefore, understanding the endogenous licencing mechanisms that prevent unwanted, excessive NLRP3 responses is important. Our new MCR grant will allow us to characterise one such mechanism that limits NLRP3 activation. This work will help us understand why NLRP3 inflammasome sometimes gets uncontrollably activated, and how we may be able to restore the control over this pathway to reduce inappropriate inflammation."

Alex Clarke will study Graves disease, the most common cause of an overactive throid gland. One of the most serious complications of Graves disease is that it can cause swelling behind the eye, pushing it forward and in some cases threatening sight. Alex said about his research "We know antibodies are important in Graves' disease, but why some patient develop eye problems is unknown. In our study, we'll use single cell analysis techniques to understand how the tissues behind the eye change in active and inactive Graves' disease, and how antibody-producing cells interact with fibroblasts to influence this. This MRC award will allow us to build our research capacity across immune diseases and disciplines, and leverage the state-of-the-art science platforms available at the Kennedy Institute."

Similar stories

The new Botnar strategy is announced

After a year as the Director of the Botnar Institute for Musculoskeletal Sciences, Professor Jonathan Rees announces a new structure and strategy that will further enhance research and treatment of bone, joint and musculoskeletal conditions.

New global health grant to improve outcomes for patients with hip fracture

Hip fracture patients in Low- and Middle-Income Countries (LMIC) in Asia are set to benefit from a new study that aims to bring best practice programmes to improve quality of life for patients and reduce healthcare costs.

NDORMS welcomes great-granddaughter of former Head of Department

Julia Strubell, great-granddaughter of Professor Josep Trueta, visited NDORMS to find out about his time here and to share her own work with staff and students.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

Better diagnosis and treatment of autoimmune diseases moves a step closer

A study published in Nature outlines a way to find the crucial peptides (protein fragments) that drive autoimmunity, as well as the immune cells that respond to them.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.